Paratek Pharmaceuticals, Inc. - FORM 8-K - EX-99.1 - COMPANY SLIDE PRESENTATION

Attached files

file	filename
8-K - FORM 8-K - Paratek Pharmaceuticals, Inc.	d461871d8k.htm

January 2013

A specialty pharmaceutical company focused on the development

and commercialization of proprietary products to address important

therapeutic needs in the field of neuroscience

Exhibit 99.1

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other

than statements of historical facts, included in this presentation are forward-looking statements. Examples of such statements

include our expectations regarding the potential market for Intermezzo®

and the potential market size for a middle of the

night sleep aid; our expectations regarding an ideal therapeutic; Purdue plans to invest approximately $100 million to support

sales and marketing over the first 12 months of commercialization of Intermezzo in the U.S., including the size, timing and

nature of such sales and marketing plans; the success of the commercial launch of Intermezzo by Purdue in the U.S.,

including continued growth in the number of Intermezzo prescriptions; our eligibility for and the receipt and size of royalty

payments from Purdue pursuant to our Collaboration Agreement, and our expectations regarding future co-promote and

royalty opportunities; intellectual property protection for Intermezzo being obtained and maintained; plans for the Phase 2

study of TO-2061, including the expected timing of receipt of final clinical

trial results; and our strategy to build a specialty

sales and marketing organization, in-license or acquire additional product candidates, and determine the future development

path for TO-2061. All of these forward-looking statements are based on estimates and assumptions by our

management that,

although we believe to be reasonable, are inherently uncertain. Forward-looking statements involve risks and uncertainties,

including, but not limited to, achieving acceptance of Intermezzo by physicians, patients and third-party payors; the impact of

competitive products and the market for Intermezzo generally; our dependence on Purdue’s commercialization efforts,

including our reliance on Purdue to set the future pricing of Intermezzo and on our Collaboration Agreement with Purdue;

obtaining, maintaining and protecting marketing and other regulatory exclusivity and intellectual property protection for

Intermezzo and TO-2061, as well as protection from generic versions of our products; competitive product commercialization;

manufacturing and supply risks for Intermezzo; adverse results from our clinical trial of TO-2061; adverse patent decisions at

the USPTO or in court; our intent and ability to carry out plans

to promote Intermezzo to psychiatrists in the United States

through our co-promotion option; our intent and ability to successfully in-license or acquire additional product candidates; and

variability in the business of Transcept generally. These and other risks are described in greater detail in the "Risk Factors"

section of Transcept periodic reports filed with the Securities and Exchange Commission. Forward-looking statements do not

reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or

investments Transcept may enter into or make. Transcept does not

assume any obligation to update any forward-looking

statements, except as may be required by law.

Forward looking statements

Dec 31 2012: ~$85M cash & equivalents, net of

$10M Intermezzo DTC investment

Neuroscience / psychiatry

First and only Rx sleep aid approved for middle-of-

the-night dosing

U.S. primary care partnership: Purdue Pharma

$29M 6-month DTC campaign: TV launch Jan 2013

600+ Purdue sales reps presenting Intermezzo

TSPT option to co-promote to psychiatrists

Transcept corporate overview

Strong balance

sheet

Therapeutic focus

Intermezzo: the first and only prescription sleep aid

approved for middle-of-the-night dosing

Intermezzo: the first and only prescription sleep aid

approved for middle-of-the-night dosing

Indication statement as approved by FDA:

–

Intermezzo

is indicated for use as needed for the

treatment of insomnia when a middle-of-the-night

awakening is followed by difficulty returning to sleep.

–

Intermezzo

is not indicated for the treatment of middle-

of-the-night insomnia when the patient has fewer than 4

hours of bedtime remaining before the planned time of

waking.

Intermezzo unit dose bedside packaging

“Intermezzo is to be taken in bed when a patient wakes in the middle

of the night and has difficulty returning to sleep. Intermezzo should

only be taken if the patient has at least 4 hours of bedtime remaining

before the planned time of waking.”

Middle of the night (MOTN) awakening:

a major unmet medical need in the insomnia category

Middle of the night (MOTN) awakening:

a major unmet medical need in the insomnia category

Large U.S. insomnia market

–

million

new

and

refill

prescriptions

(1)

Insomnia

under-treated

condition

(2)

–

million

patients

receive

(3)

–

are

not

diagnosed

treated

physician

(2,3)

MOTN

awakening:

the

most

common

insomnia

symptom

(4)

–

35%

Americans

suffer

from

MOTN

awakenings

least

week

(4)

–

>90% report awakenings persist more than six months;

50%

report

awakenings

persist

than

five

years

(5)

(1)

IMS

Oct

2010

Sep

2011;

(2)

Institute

Medicine

Sleep

disorders

and

sleep

deprivation

Apr.

2006;

(3)

BluePrint

Research

Group;

(4) Ohayon,

Nocturnal awakenings and comorbid disorders in the American general population. J of Psych Research (2009); (5) Ohayon, Difficulty

resuming

inability

resume

sleep

and

the

links

daytime

impairment,

Psych

Research

(2009).

Commonly prescribed sleep aids are indicated

only for bedtime use

Commonly prescribed sleep aids are indicated

only for bedtime use

MOTN awakenings typically do not occur every night

7-8 hr sleep aids (Ambien

, Ambien CR

, Lunesta

) require

bedtime prophylactic dosing to prevent awakenings

An ideal therapeutic would:

–

Be used only at the time patients need help returning to sleep,

not every night in advance of a problem that may not occur

–

Return patients to sleep rapidly

–

Be effective despite the low dose necessary to avoid next day

residual effects when used in the middle of the night

Intermezzo: the first and only sleep aid approved for

middle-of-the night dosing

Intermezzo: the first and only sleep aid approved for

middle-of-the night dosing

Novel zolpidem formulation

–

Sublingual tablet

–

Bicarbonate-carbonate buffers

Approved dose

–

1.75 mg in women & patients > 65 years

–

3.5 mg in men < 65 years

Rapidly absorbed in both men and women

Effective vs. placebo in sleep laboratory & outpatient studies

Instructions to patients

–

Take Intermezzo “while in bed”

–

“When you wake up in the morning, be sure that at least 4 hours have passed

since you have taken Intermezzo

and you feel fully awake before driving. Do

not do dangerous activities until you know how Intermezzo

affects you.”

Purdue commercialization agreement:

key Transcept benefits

Purdue commercialization agreement:

key Transcept benefits

Base royalty: mid-teens up to mid 20% level on net sales

Milestone payments

–

Received: $25M up front + $20M for IP-related milestones

–

Potential: Up to an additional $70M related to net sales targets

Co-promote option: foundation for a commercial future

–

Option to exercise co-promote extends through August 2015

–

After option exercise, Transcept must wait 8 to 15 months to begin

promotion, depending on when in the calendar year the exercise is made

–

Co-promote royalty

•

Ranges from 40% (if option had been exercised by Apr 2012) to

22% (if option is exercised in Aug 2015) of psychiatrist net sales

•

Net sales qualifying for this additional co-promote royalty is capped

at 15% of total Intermezzo annual net U.S. sales

200

400

600

800

1000

1200

1400

1600

1800

Week post-launch

Intermezzo

Thanksgiving holiday week

Intermezzo weekly TRx as of 12/21/12

Purdue DTC campaign launch January 2013

Intermezzo ad placement on leading TV networks

$29 M six-month DTC advertising campaign

–

Purdue contribution $19M; Transcept contribution $10M

–

Television ads to commence January 2013

New sales force commitment with 600+ reps

–

Purdue analgesic sales force of 525 sales

representatives will present Intermezzo

–

Dedicated Intermezzo contract sales force of 90 sales

representatives to continue to call on top prescribers of

prescription sleep aids

DTC launch and broadened Intermezzo

commercialization effort

DTC launch and broadened Intermezzo

commercialization effort

Intermezzo:

intellectual property

Intermezzo:

intellectual property

Four Intermezzo U.S. patents issued

Methods for Treating Middle

of-

the

Night Insomnia

8,242,131

2029

Compositions for Delivering Hypnotic Agents across

the Oral Mucosa and Methods of Use thereof

7,682,628

2025

U.S. patent title

Patent no.

Expiration

Compositions

for Treating Insomnia

8,252,809

2025

Compositions for Delivering Hypnotic Agents across

the Oral Mucosa and Methods of Use thereof

7,658,945

2027

Financial overview

Financial position

(1)

Financial position

(1)

December 31, 2012

Cash, equivalents & investments: ~$85 M

(2)

Shares outstanding

19 M

Options / warrants / other:

3 M

Total:

22 M

Employees:

(3)

(1)

All numbers are unaudited.

(2)

Net of $10M Intermezzo DTC investment.

(3)

On Jan 4, 2013, Transcept announced a reduction in force of 8 employees

to be implemented throughout the first quarter of 2013.

Intermezzo launched April 2012

–

First approval for middle of the night awakening

–

Large potential market

–

Significant royalty and co-promote opportunities

–

600+ sales reps

–

DTC launch Jan 2013

Strong balance sheet

Key investment highlights

Intermezzo

is a registered trademark of Purdue Pharmaceuticals L.P.

Ambien

and Ambien CR

are registered trademarks of sanofi-aventis

Lunesta

is a registered trademark of Sunovion Pharmaceuticals Inc.

Paratek Pharmaceuticals, Inc. - FORM 8-K - EX-99.1 - COMPANY SLIDE PRESENTATION - January 7, 2013

Attached files

Paratek Pharmaceuticals, Inc. Reports